Early clinical evidence had indicated an advantage for intermittent androgen deprivation (IAD) over continuous androgen deprivation (CAD) in men with hormone-sensitive metastatic prostate cancer (HSMPC). Now, a randomized phase III trial of over 1,500 men showed that IAD was not inferior to CAD for men with HSMPC but was significantly inferior to CAD for men with minimal disease, suggesting CAD is better for this subgroup.
ORIGINAL RESEARCH PAPER
Hussain, M. et al. Intermittent (IAD) versus continuous androgen depriviation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (Pts): Results of S9346 9INT-0162), an international phase III trial. J. Clin. Oncol. 30 (Suppl.), LBA4 (2012)
Rights and permissions
About this article
Cite this article
Continuous dosing is preferred option for prostate cancer. Nat Rev Clin Oncol 9, 428 (2012). https://doi.org/10.1038/nrclinonc.2012.108
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2012.108
